Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers

Mutant RAS has remained recalcitrant to targeted therapy efforts. Here we demonstrate that combined treatment with poly ADP ribose polymerase (PARP) inhibitors and MEK inhibitors evokes unanticipated, synergistic cytotoxic effects in vitro and in vivo in multiple RAS mutant tumor models across tumor...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Sci Transl Med
Auteurs principaux: Sun, Chaoyang, Fang, Yong, Yin, Jun, Chen, Jian, Ju, Zhenlin, Zhang, Dong, Chen, Xiaohua, Vellano, Christopher P., Jeong, Kang Jin, Ng, Patrick Kwok-Shing, Eterovic, A. Karina, Bhola, Neil H., Lu, Yiling, Westin, Shannon N, Grandis, Jennifer R., Lin, Shiaw-Yih, Scott, Kenneth L., Peng, Guang, Brugge, Joan, Mills, Gordon B.
Format: Artigo
Langue:Inglês
Publié: 2017
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5919217/
https://ncbi.nlm.nih.gov/pubmed/28566428
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aal5148
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires